Terminal complement complex
complexTerminal complement complex activation marks systemic inflammatory cascade and prothrombotic state in acute MI.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleComplement activation marker; inflammatory driver in STEMI and thrombosis.
Also acts inCoagulation / thrombus
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I48
C — confounder / Type-II64
A — assay feasibility58
E — evidence strength25
T1DI (composite)6
Specificity differential (R−C)-15.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (citrate for coagulation complexes)
Collection tube
Sodium citrate 3.2% (light blue-top) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich ELISA against neo-complex epitope
Reagent / substrate
Antibody pair recognizing the assembled complex
Platform
ELISA plate
Turnaround · availability
Research / send-out · Research/specialized
Literature evidence(1)
- Combined complement and coagulation activation in ST-elevation myocardial infarction: associations with myocardial injury and dysfunction.Frontiers in immunology · 2025 · PMID 41262246 · doi